194660-14-5

Usage

Uses

Used in Pharmaceutical Industry:
Desotamide is used as an inhibitor for bacterial RNA polymerase due to its ability to produce salinamide A. This application is significant in the development of new antibiotics and antimicrobial agents, as it can help combat bacterial infections by disrupting the bacteria's ability to transcribe RNA, thereby inhibiting their growth and reproduction.
Used in Research and Development:
In the field of research and development, desotamide serves as a valuable compound for studying the mechanisms of bacterial RNA polymerase inhibition. This can lead to a better understanding of bacterial transcription processes and the development of novel strategies to combat antibiotic resistance.
Used in Drug Discovery:
Desotamide's potential as a lead compound in drug discovery is noteworthy. Its ability to inhibit bacterial RNA polymerase makes it a promising candidate for the development of new drugs targeting bacterial infections, particularly in the context of increasing antibiotic resistance.

InChI:InChI=1/C35H52N8O7/c1-7-20(6)30-35(50)42-27(15-28(36)44)31(46)38-17-29(45)39-26(14-21-16-37-23-11-9-8-10-22(21)23)33(48)40-24(12-18(2)3)32(47)41-25(13-19(4)5)34(49)43-30/h8-11,16,18-20,24-27,30,37H,7,12-15,17H2,1-6H3,(H2,36,44)(H,38,46)(H,39,45)(H,40,48)(H,41,47)(H,42,50)(H,43,49)/t20-,24+,25-,26+,27+,30+/m1/s1

Upstream product

• 29022-11-5 N-(fluoren-9-ylmethoxycarbonyl)glycine 
• 35661-60-0 Fmoc-Leu-OH 
• 71989-23-6 Fmoc-Ile-OH 
• 35661-60-0 N-(9-fluorenylmethoxycarbonyl)-D-leucine 
• 144120-53-6 (S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(allyloxy)-4-oxobutanoic acid 
• 143824-78-6 3-[(S)-2-carboxy-2-(9H-fluoren-9-ylmethoxycarbonylamino)ethyl]indole-1-carboxylic acid tert-butyl ester 

Downstream Products

• 128424-93-1 L-FDAA-L-Leu 
• 128425-06-9 L-FDAA-D-leucine 
• 141779-59-1 FDAA-L-Asp 

Relevant academic research and scientific papers

Total Synthesis and Antibacterial Study of Cyclohexapeptides Desotamide B, Wollamide B and Their Analogs

As natural-product-derived antibiotics, desotamides A?–?D and wollamides exhibit growth inhibitory activity against Gram-posivite bacteria (IC50 0.6?–?7?μm) and are noncytotoxic to mammalian cells (IC50?>?30?μm). Herein we firstly re

Solid-Phase Synthesis and Antibacterial Activity of Cyclohexapeptide Wollamide B Analogs

Herein we report the antibacterial structure-activity relationships of cyclic hexapeptide wollamide analogs derived from solid-phase library synthesis. Wollamide B, a cyclic hexapeptide natural product, has been previously found to have activity against Mycobacterium bovis. To further evaluate its antimycobacterial/antibacterial potential, 27 peptides including wollamides A/B, and desotamide B, were synthesized and subsequently tested against a panel of clinically significant bacterial pathogens. Biological evaluation revealed that the cyclic scaffold, amide functionality in position I, tryptophan residue in position V, and the original stereochemistry pattern of the core scaffold were key for antituberculosis and/or antibacterial activity. In addition, against M. tuberculosis and Gram-positive bacteria, residues in position II and/or VI greatly impacted antibacterial activity and selectivity. Wollamides A (3) and B (2) along with their corresponding II (l-Leu) analog 10 retained the most promising antituberculosis activity, with the lowest minimum inhibitory concentration (MIC) against virulent M. tuberculosis H37Rv (MIC = 1.56 μg/mL), as well as desirable selectivity indices (>100). Importantly, the antimicrobial activities of wollamides A and B do not result from disruption of the bacterial membrane, warranting further investigation into their mechanism of action.